S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

$42.85
-0.35 (-0.81%)
(As of 03/27/2024 ET)
Today's Range
$42.67
$44.17
50-Day Range
$41.67
$52.35
52-Week Range
$2.10
$53.82
Volume
251,726 shs
Average Volume
302,820 shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.60

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
29.8% Upside
$55.60 Price Target
Short Interest
Bearish
12.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.98mentions of Soleno Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$141,229 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.23) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

114th out of 939 stocks

Electromedical Equipment Industry

2nd out of 18 stocks

SLNO stock logo

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

SLNO Stock News Headlines

Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up to $43.35
SLNO Apr 2024 40.000 put
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
SLNO Apr 2024 35.000 put
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Soleno Therapeutics Inc.
SLNO Apr 2024 65.000 call
SLNO Mar 2024 40.000 call
SLNO Mar 2024 22.500 put
SLNO Mar 2024 60.000 call
SLNO Mar 2024 45.000 put
Soleno Therapeutics Inc (SLNO)
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:SLNO
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$55.60
High Stock Price Target
$93.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+29.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-38,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.16 per share

Miscellaneous

Free Float
23,112,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
-1.53
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 54)
    President, CEO, COO & Director
    Comp: $835.2k
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 60)
    Chief Financial Officer
    Comp: $539k
  • Ms. Patricia C. Hirano (Age 58)
    Vice President of Regulatory Affairs
    Comp: $423.8k
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., Senior Vice President of Drug Development
  • Ms. Meredith Manning M.B.A. (Age 51)
    Chief Commercial Officer
  • Ms. Kristen Yen M.S. (Age 55)
    Vice President of Clinical Operations
    Comp: $317.19k

SLNO Stock Analysis - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 1-year price targets for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $93.00. On average, they predict the company's share price to reach $55.60 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2024?

Soleno Therapeutics' stock was trading at $40.25 on January 1st, 2024. Since then, SLNO shares have increased by 6.5% and is now trading at $42.85.
View the best growth stocks for 2024 here
.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,300,000 shares, an increase of 36.9% from the February 29th total of 1,680,000 shares. Based on an average daily trading volume, of 294,800 shares, the days-to-cover ratio is presently 7.8 days. Approximately 12.2% of the shares of the stock are sold short.
View Soleno Therapeutics' Short Interest
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Wednesday, March, 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02.

When did Soleno Therapeutics' stock split?

Shares of Soleno Therapeutics reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (27.60%), Carlyle Group Inc. (9.37%), Nantahala Capital Management LLC (9.37%), Vestal Point Capital LP (4.26%), Vanguard Group Inc. (3.18%) and Vanguard Group Inc. (3.18%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLNO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners